Found 72 Enz. Inhib. hit(s) with Target = 'Platelet-derived growth factor receptor alpha [D842V]' TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:KIT, KIT mutant, and PDGFRα mutant kinase profiling was performed with recombinant enzymes including wild-type KIT, KIT V560G, KIT V559D/T670I, ...More data for this Ligand-Target Pair
